Reviews the decade-long progress in EGFR-targeted therapies and introduces the rationale for first-line dual inhibition.
Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
2
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
3
Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
4
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
5
